FibroBiologics (FBLG) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$4.1M

Net income growth (year over year)

+11.61%

Net margin

—

Return on equity

−660.08%

EPS (trailing twelve months)

−$5.10

Book value per share

$0.76

P/E (trailing twelve months)

—

Price to book

1.38

Debt to assets

41.53%

Payout ratio

—

Dividend yield

—

Company profile

FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.

• How do I buy stock in FibroBiologics (FBLG)?

  FBLG trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.